Compare SITE & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SITE | GPCR |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional and commerical equipment | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.3B |
| IPO Year | 2016 | 2023 |
| Metric | SITE | GPCR |
|---|---|---|
| Price | $148.12 | $78.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $150.10 | $103.09 |
| AVG Volume (30 Days) | 682.4K | ★ 1.3M |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.08 | N/A |
| Revenue | ★ $4,672,300,000.00 | N/A |
| Revenue This Year | $5.87 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $48.75 | ★ N/A |
| Revenue Growth | ★ 4.00 | N/A |
| 52 Week Low | $101.25 | $13.22 |
| 52 Week High | $154.00 | $94.90 |
| Indicator | SITE | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 58.87 | 50.11 |
| Support Level | $139.82 | $72.10 |
| Resistance Level | $152.23 | $92.06 |
| Average True Range (ATR) | 4.02 | 4.34 |
| MACD | -0.27 | -2.65 |
| Stochastic Oscillator | 60.50 | 29.97 |
SiteOne Landscape Supply Inc is a supplier of tools and equipment. The company serves various businesses which include wholesale irrigation, outdoor lighting, nursery, landscape supplies, grass seeds, and fertilizers, turf protection products, turf care equipment, and golf course accessories for green industry professionals mainly in the United States and Canada. Its product portfolio includes irrigation supplies, fertilizer and herbicides, landscape accessories, nursery goods, natural stones and blocks, outdoor lighting and ice melt products and other products.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.